Radiopharm Theranostics
Radiopharm Theranostics is an Australia-based radiopharmaceutical company that leads 3 cancer trials in OnCo, testing the radiopharmaceuticals 161Tb-RAD402, 177Lu-BetaBart and the PET tracer RAD101 in prostate cancer, colorectal cancer, non-small-cell lung cancer and ovarian cancer.
Overview
Radiopharm Theranostics is a clinical-stage company developing radiopharmaceuticals for the diagnosis and treatment of cancer, using nanobody, antibody, small-molecule and peptide platforms directed at targets other than PSMA, FAP and SSTR2. It has a joint venture with MD Anderson Cancer Center and is listed in Australia and on Nasdaq. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT07189871 (phase 1/2, 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Me...), NCT07259213 (phase 1/2, A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC) and NCT06777433 (phase 2, Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Similar pages
not linked directly; found by shared links- TrialA Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Shares Endometrial cancer, Ovarian cancer, Prostate cancer, Colorectal cancer.
- TrialA Study of DM002 in Patients With Advanced Solid Tumors
Shares Endometrial cancer, Ovarian cancer, Prostate cancer, Colorectal cancer.
- TrialThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Shares Endometrial cancer, Ovarian cancer, Prostate cancer, Colorectal cancer.
- TrialA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Shares Endometrial cancer, Cervical cancer, Prostate cancer, Non-small-cell lung cancer.
- TreatmentVudalimab
Shares Endometrial cancer, Cervical cancer, Ovarian cancer, Prostate cancer.
- TrialA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
Shares Endometrial cancer, Ovarian cancer, Colorectal cancer, Non-small-cell lung cancer.
- CompanyOutcomes4Me
Shares Endometrial cancer, Ovarian cancer, Prostate cancer, Colorectal cancer.
- PersonJalid Sehouli
Shares Endometrial cancer, Cervical cancer, Ovarian cancer.